CN101684108A - 2-(3-氰基-4-异丁氧基苯基)-4-甲基-5-噻唑甲酸及其组合物 - Google Patents
2-(3-氰基-4-异丁氧基苯基)-4-甲基-5-噻唑甲酸及其组合物 Download PDFInfo
- Publication number
- CN101684108A CN101684108A CN200910030753A CN200910030753A CN101684108A CN 101684108 A CN101684108 A CN 101684108A CN 200910030753 A CN200910030753 A CN 200910030753A CN 200910030753 A CN200910030753 A CN 200910030753A CN 101684108 A CN101684108 A CN 101684108A
- Authority
- CN
- China
- Prior art keywords
- febustat
- minute
- new crystal
- crystal
- febuxostat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 8
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 title abstract description 12
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 title abstract description 6
- 235000019253 formic acid Nutrition 0.000 title abstract description 6
- 239000013078 crystal Substances 0.000 claims abstract description 86
- BQSJTQLCZDPROO-UHFFFAOYSA-N febuxostat Chemical compound C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)S1 BQSJTQLCZDPROO-UHFFFAOYSA-N 0.000 claims abstract description 25
- 229960005101 febuxostat Drugs 0.000 claims abstract description 25
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 claims abstract description 9
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229940116269 uric acid Drugs 0.000 claims abstract description 9
- 201000010099 disease Diseases 0.000 claims abstract description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims abstract description 5
- 230000015572 biosynthetic process Effects 0.000 claims description 24
- 238000009413 insulation Methods 0.000 claims description 12
- 239000000843 powder Substances 0.000 claims description 8
- 238000001291 vacuum drying Methods 0.000 claims description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 5
- 238000002425 crystallisation Methods 0.000 claims description 3
- 230000008025 crystallization Effects 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- 229910016523 CuKa Inorganic materials 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 238000005755 formation reaction Methods 0.000 description 22
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 239000000126 substance Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 238000000634 powder X-ray diffraction Methods 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 4
- 238000001460 carbon-13 nuclear magnetic resonance spectrum Methods 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 238000004896 high resolution mass spectrometry Methods 0.000 description 2
- 239000011122 softwood Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000012056 up-stream process Methods 0.000 description 2
- 235000020985 whole grains Nutrition 0.000 description 2
- XILIYVSXLSWUAI-UHFFFAOYSA-N 2-(diethylamino)ethyl n'-phenylcarbamimidothioate;dihydrobromide Chemical compound Br.Br.CCN(CC)CCSC(N)=NC1=CC=CC=C1 XILIYVSXLSWUAI-UHFFFAOYSA-N 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229940124186 Dehydrogenase inhibitor Drugs 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- 240000006474 Theobroma bicolor Species 0.000 description 1
- 108010091383 Xanthine dehydrogenase Proteins 0.000 description 1
- 102000005773 Xanthine dehydrogenase Human genes 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 229910000400 magnesium phosphate tribasic Inorganic materials 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- -1 polyoxyethylene Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000001757 thermogravimetry curve Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Images
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
衍射角(2θ) | D值 | I/I0 |
7.20 | 12.2675 | 28 |
12.82 | 6.8995 | 100 |
14.44 | 6.1289 | 2 |
16.18 | 5.4735 | 3 |
16.52 | 5.3616 | 4 |
17.50 | 5.0635 | 2 |
19.04 | 4.6573 | 2 |
19.58 | 4.5301 | 7 |
21.02 | 4.2229 | 2 |
21.96 | 4.0442 | 4 |
22.72 | 3.9106 | 4 |
23.00 | 3.8636 | 3 |
23.84 | 3.7293 | 3 |
24.28 | 3.6628 | 2 |
24.72 | 3.5985 | 2 |
25.88 | 3.4398 | 4 |
26.70 | 3.3360 | 4 |
27.16 | 3.2805 | 2 |
27.92 | 3.1929 | 3 |
28.52 | 3.1271 | 3 |
29.12 | 3.0640 | 2 |
30.90 | 2.8915 | 2 |
32.66 | 2.7396 | 2 |
34.10 | 2.6271 | 2 |
36.74 | 2.4442 | 2 |
38.34 | 2.3458 | 2 |
39.84 | 2.2608 | 2 |
41.66 | 2.1662 | 2 |
44.82 | 2.0205 | 2 |
47.40 | 1.9164 | 2 |
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009100307536A CN101684108B (zh) | 2009-04-15 | 2009-04-15 | 2-(3-氰基-4-异丁氧基苯基)-4-甲基-5-噻唑甲酸及其组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009100307536A CN101684108B (zh) | 2009-04-15 | 2009-04-15 | 2-(3-氰基-4-异丁氧基苯基)-4-甲基-5-噻唑甲酸及其组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101684108A true CN101684108A (zh) | 2010-03-31 |
CN101684108B CN101684108B (zh) | 2012-01-11 |
Family
ID=42047516
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009100307536A Active CN101684108B (zh) | 2009-04-15 | 2009-04-15 | 2-(3-氰基-4-异丁氧基苯基)-4-甲基-5-噻唑甲酸及其组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101684108B (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011007895A1 (ja) * | 2009-07-15 | 2011-01-20 | 帝人ファーマ株式会社 | 貧溶媒添加法による2-(3-シアノ-4-イソブチルオキシフェニル)-4-メチル-5-チアゾールカルボン酸の結晶多形体の製造方法 |
WO2012020272A2 (en) | 2010-08-13 | 2012-02-16 | EGIS GYÓGYSZERGYÁR Nyilvánosan Müködö Részvénytársaság | New salts, polymorphs and solvates of a pharmaceutical active ingredient |
US8415481B2 (en) | 2009-06-10 | 2013-04-09 | Teva Pharmaceuticals Usa, Inc. | Crystalline form of febuxostat |
CN103739568A (zh) * | 2014-02-07 | 2014-04-23 | 浙江普洛康裕制药有限公司 | 2-(3-氰基-4-异丁氧基苯基)-4-甲基噻唑-5-甲酸a晶型的制备方法 |
-
2009
- 2009-04-15 CN CN2009100307536A patent/CN101684108B/zh active Active
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8415481B2 (en) | 2009-06-10 | 2013-04-09 | Teva Pharmaceuticals Usa, Inc. | Crystalline form of febuxostat |
US8609856B2 (en) | 2009-06-10 | 2013-12-17 | Teva Pharmaceuticals Usa, Inc. | Crystalline forms of Febuxostat |
US8742129B2 (en) | 2009-06-10 | 2014-06-03 | Teva Pharmaceutical Industries Ltd. | Crystalline forms of febuxostat |
WO2011007895A1 (ja) * | 2009-07-15 | 2011-01-20 | 帝人ファーマ株式会社 | 貧溶媒添加法による2-(3-シアノ-4-イソブチルオキシフェニル)-4-メチル-5-チアゾールカルボン酸の結晶多形体の製造方法 |
US8735596B2 (en) | 2009-07-15 | 2014-05-27 | Teijin Pharma Limited | Process for producing crystals of polymorphic 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecaboxylic acid by poor-solvent addition method |
WO2012020272A2 (en) | 2010-08-13 | 2012-02-16 | EGIS GYÓGYSZERGYÁR Nyilvánosan Müködö Részvénytársaság | New salts, polymorphs and solvates of a pharmaceutical active ingredient |
CN103739568A (zh) * | 2014-02-07 | 2014-04-23 | 浙江普洛康裕制药有限公司 | 2-(3-氰基-4-异丁氧基苯基)-4-甲基噻唑-5-甲酸a晶型的制备方法 |
CN103739568B (zh) * | 2014-02-07 | 2015-09-16 | 浙江普洛康裕制药有限公司 | 2-(3-氰基-4-异丁氧基苯基)-4-甲基噻唑-5-甲酸a晶型的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN101684108B (zh) | 2012-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1970547B (zh) | 非布司他的晶型及其制备方法 | |
CN102219783B (zh) | 盐酸维拉佐酮及其组合物 | |
US20150344435A1 (en) | Process for preparating ivabradine hydrochloride form iv and methods of treatment of disease using ivabradine hydrochloride form iv | |
CN101691372B (zh) | 枸橼酸爱地那非晶型c及其制备方法和用途 | |
CN101671337B (zh) | 枸橼酸爱地那非晶型a及其制备方法和用途 | |
CN101684108B (zh) | 2-(3-氰基-4-异丁氧基苯基)-4-甲基-5-噻唑甲酸及其组合物 | |
CN101830903B (zh) | 枸橼酸爱地那非晶型o及其制备方法和应用 | |
CN102241608A (zh) | 瑞替加滨化合物及其组合物 | |
CN101774937B (zh) | N-[2-(7-甲氧基-1-萘基)乙基]乙酰胺及其组合物 | |
CN102453021A (zh) | 来那度胺的新晶型及其制备方法 | |
CN101698668B (zh) | 枸橼酸爱地那非晶型v及其制备方法和用途 | |
EP1070078B1 (en) | Form vi 5,6-dichloro-2-(isopropylamino)-1-beta-l-ribofuranosyl)-1h-benzimidazole | |
CN101619039B (zh) | 2-(4-乙基-1-哌嗪基)-4-(4-氟苯基)-5,6,7,8,9,10-六氢芳辛并[b]吡啶及其组合物 | |
CN101607960B (zh) | 醋茶溴索及其组合物 | |
CN101899056A (zh) | 普拉格雷氢溴酸盐多晶型物及其制备方法 | |
CN106279017A (zh) | 贝达喹啉晶型、组合物及其制备方法 | |
CN102225929A (zh) | 一种稳定的盐酸法舒地尔水合物化合物 | |
CN101735040B (zh) | 索法酮的晶型ⅲ及其制备方法和用途 | |
CN101781194B (zh) | 索法酮的晶型ⅴ及其制备方法和用途 | |
CN101817742B (zh) | 索法酮的晶型ⅹ及其制备方法和用途 | |
CN101735039B (zh) | 索法酮的晶型ⅱ及其制备方法和用途 | |
CN103848845B (zh) | 普拉格雷倍半水合物及其制备方法 | |
CN101735038B (zh) | 索法酮的晶型ⅰ及其制备方法和用途 | |
CN101817741B (zh) | 索法酮的晶型ⅸ及其制备方法和用途 | |
CN101781193B (zh) | 索法酮的晶型ⅳ及其制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: TIANJIN HANKANG PHARMACEUTICAL BIOTECHNOLOGY CO., Free format text: FORMER OWNER: JIANGSU ZHENGDA FENGHAI PHARMACEUTICAL CO., LTD. Effective date: 20110919 Free format text: FORMER OWNER: TIANJIN HANKANG PHARMACEUTICAL BIOTECHNOLOGY CO., LTD. |
|
C41 | Transfer of patent application or patent right or utility model | ||
C53 | Correction of patent for invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Wang Zhifeng Inventor before: Wang Zhifeng Inventor before: Xu Junfu Inventor before: Lu Bin |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: WANG ZHIFENG XU JUNFU LU BIN TO: WANG ZHIFENG Free format text: CORRECT: ADDRESS; FROM: 224100 YANCHENG, JIANGSU PROVINCE TO: 300203 HEXI, TIANJIN |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20110919 Address after: 300203, Tianjin Dagu South Road, respect 4, 3, Hexi District Applicant after: Tianjin Hankang Pharmaceutical Biotechnology Co., Ltd. Address before: 224100 No. 103 East Health Road, Dafeng City, Jiangsu Province Applicant before: Jiangsu Zhengda Fenghai Pharmaceutical Co., Ltd. Co-applicant before: Tianjin Hankang Pharmaceutical Biotechnology Co., Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
DD01 | Delivery of document by public notice |
Addressee: Huang Xin Document name: Notification of Passing Examination on Formalities |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20180117 Address after: 300457 Tianjin Development Zone Dongting Road 220 international biology and Medicine Institute Experimental Building 6 layer S614 Patentee after: Tianjin Han Yi Pharmaceutical Technology Co., Ltd. Address before: 300203, Tianjin Dagu South Road, respect 4, 3, Hexi District Patentee before: Tianjin Hankang Pharmaceutical Biotechnology Co., Ltd. |